Aerie Pharmaceuticals is a clinical-stage biotechnology company that is dedicated to the discovery and development of novel treatments for glaucoma. The company has identified two highly selective Rho-kinase (ROCK) inhibitors to lower intraocular pressure by improving outflow of fluid via the trabecular pathway with the potential of restoring normal function. NASDAQ: AERI